Ambrx Lands New Merck Serono Deal, This Time In Multiple Sclerosis
After boosting staff by 50 percent, Ambrx has cash runway through late 2011 or 2012, CEO says.
After boosting staff by 50 percent, Ambrx has cash runway through late 2011 or 2012, CEO says.